Comparison of a dietary portfolio diet of cholesterol-lowering foods and a statin on LDL particle size phenotype in hypercholesterolaemic participants

British Journal of Nutrition

Volumn 98, Issue 6, 2007, Pages 1229-1236

  Gigleux, Iris ^a   Jenkins, David J A ^b   Kendall, Cyril W C ^b   Marchie, Augustine ^b   Faulkner, Dorothea A ^b   Wong, Julia M W ^b   De Souza, Russell ^b   Emam, Aadeh ^b   Parker, Tina I ^b   Trautwein, Elke A ^c   Lapsley, Karen G ^d   Connelly, Philip W ^b   Lamarche, Benoît ^a  

^a LAVAL UNIVERSITY   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNILEVER RESEARCH VLAARDINGEN   (Netherlands)

^d Almond Board of California   (United States)

Author keywords

Drugs; Lipids; Lipoproteins; Nutrition

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PHYTOSTEROL; SOYBEAN PROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ALMOND; ARTICLE; CARDIOVASCULAR EFFECT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DIETARY FIBER; DRUG RESPONSE; EVENING DOSAGE; FEMALE; FOOD COMPOSITION; HEALTH EDUCATION; HUMAN; HYPERCHOLESTEROLEMIA; LOW FAT DIET; MALE; OUTPATIENT CARE; PARTICLE SIZE; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

AGED; ANALYSIS OF VARIANCE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIET, FAT-RESTRICTED; DIETARY FATS; DIETARY FIBER; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPIDS; LOVASTATIN; MALE; MIDDLE AGED; PARTICLE SIZE; PHYTOSTEROLS; RISK;

EID: 36649000691     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114507781461     Document Type: Article

References (35)

1. Krauss RM & Burke DJ (1982) Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 23, 97-104.
2. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ Despres JP (1997) Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 95 69-75.
3. St Pierre AC, Ruel IL, Cantin B, Dagenais GR, Bernard PM, Despres JP Lamarche B (2001) Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 104, 2295-2299.
4. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389.
5. Anon MRC/BHF (2002) Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360, 7-22.
6. Grundy SM (1988) HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319, 24-33.
7. Zhao SP, Hollaar L, 't Hooft FM, Smelt AH, Gevers JA & van der Leuven LA (1991) Effect of simvastatin on the apparent size of LDL particles in patients with type IIB hyperlipoproteinemia. Clin Chim Acta 203 109-117.
8. Yuan JN, Tsai MY, Hegland J & Hunninghake DB (1991) Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 87, 147-157.
9. Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ & Caslake MJ (2002) Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 164, 129-145.
10. Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R & Chapman MJ (2002) Dose-dependent action of atorvastatin in type JIB hyperlipidemia: Preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 163, 287-296.
11. Matz W, Scharnagl H, Abletshauser C, Hoffmann MM, Berg A, Keul J, Wieland H & Baumstark MW (2001) Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation 103, 1942-1948.
12. Superko HR, Krauss RM & DiRicco C (1997) Effect of fluvastatin on low-density lipoprotein peak particle diameter. Am J Cardiol 80 78-81.
13. Tilly-Kiesi M (1991) The effect of lovastatin treatment on lowdensity lipoprotein hydrated density distribution and composition in patients with intermittent claudication and primary hypercholesterolemia. Metabolism 40, 623-628.
14. Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S & Kris-Etherton PM (1999) Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: A meta-analysis. Am J Clin Nutr 69, 632-646.
15. Anon (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285, 2486-2497.
16. Krauss RM, Eckel RH, Howard B, et al. (2000) AHA Dietary Guidelines: Revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 102, 2284-2299.
17. Jenkins DJ, Kendall CW, Marchie A, et al. (2005) Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am J Clin Nutr 81, 380-387.
18. Almario RU, Vonghavaravat V, Wong R & Kasim-Karakas SE (2001) Effects of walnut consumption on plasma fatty acids and lipoproteins in combined hyperlipidemia. Am J Clin Nutr 74, 72-79.
19. Charest A, Desroches S, Vanstone CA, Jones PJ & Lamarche B (2004) Unesterified plant sterols and stanols do not affect LDL electrophoretic characteristics in hypercholesterolemic subjects. J Nutr 134 592-595.
20. Charest A, Vanstone C, St Onge MP, Parson W, Jones PJ & Lamarche B (2005) Phytosterols in nonfat and low-fat beverages have no impact on the LDL size phenotype. Eur J Clin Nutr 59, 801-804.
21. Davy BM, Davy KP, Ho RC, Beske SD, Davrath LR & Melby CL (2002) High-fiber oat cereal compared with wheat cereal consumption favorably alters LDL-cholesterol subclass and particle numbers in middle-aged and older men. Am J Clin Nutr 76, 351-358.
22. Desroches S, Mauger JF, Ausman LM, Lichtenstein AH & Lamarche B (2004) Soy protein favorably affects LDL size independently of isoflavones in hypercholesterolemic men and women. J Nutr 134, 574-579.
23. Matvienko OA, Lewis DS, Swanson M, Arndt B, Rainwater DL, Stewart J & Alekel DL (2002) A single daily dose of soybean phytosterols in ground beef decreases serum total cholesterol and LDL cholesterol in young, mildly hypercholesterolemic men. Am J Clin Nutr 76, 57-64.
24. Merz-Demlow BE, Duncan AM, Wangen KE, Xu X, Carr TP, Phipps WR & Kurzer MS (2000) Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women. Am J Clin Nutr 71, 1462-1469.
25. Wangen KE, Duncan AM, Xu X & Kurzer MS (2001) Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. Am J Clin Nutr 73, 225-231.
26. Varady KA, St Pierre AC, Lamarche B & Jones P (2005) Effect of plant sterols and endurance training on LDL particle size and distribution in previously sedentary hypercholesterolemic adults. Eur J Clin Nutr 59, 518-525.
27. Behall KM, Scholfield DJ & Hallfrisch J (2004) Diets containing barley significantly reduce lipids in mildly hypercholesterolemic men and women. Am J Clin Nutr 80, 1185-1193.
28. Lamarche B, Desroches S, Jenkins DJ, et al. (2004) Combined effects of a dietary portfolio of plant sterols, vegetable protein, viscous fibre and almonds on LDL particle size. Br J Nutr 92 657-663.
29. Desroches S, Archer WR, Paradis ME, Deriaz O, Couture P, Bergeron J, Bergeron N & Lamarche B (2006) Baseline plasma C-reactive protein concentrations influence lipid and lipoprotein responses to low-fat and high monounsaturated fatty acid diets in healthy men. J Nutr 136, 1005-1011.
30. Erlinger TP, Miller ERIII, Charleston J & Appel LJ (2003) Inflammation modifies the effects of a reduced-fat low-cholesterol diet on lipids: results from the DASH-sodium trial. Circulation 108, 150-154.
31. Hilpert KF, Kris-Etherton PM & West SG (2005) Lipid response to a low-fat diet with or without soy is modified by C-reactive protein status in moderately hypercholesterolemic adults. J Nutr 135 1075-1079.
32. Jenkins DJ, Kendall CW, Marchie A, et al. (2005) Direct comparison of dietary portfolio vs statin on C-reactive protein. Eur J Clin Nutr 59, 851-860.
33. Jenkins DJ, Kendall CW, Faulkner D, et al. (2002) A dietary portfolio approach to cholesterol reduction: Combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. Metabolism 51, 1596-1604.
34. Pearson TA, Mensah GA, Alexander RW, et al. (2003) Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499-511.
35. Yudkin JS, Kumari M, Humphries SE & Mohamed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis 148, 209-214.